PSMD8抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07566(PSMD8 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07566(PSMD8 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PSMD8 antibody targets the 26S proteasome regulatory subunit PSMD8. a key component of the ubiquitin-proteasome system (UPS) responsible for protein degradation. PSMD8. also known as ASAG or AF010453. is part of the 19S regulatory particle that recognizes ubiquitinated substrates, unfolds them, and translocates them into the proteasome’s catalytic core for proteolysis. This subunit plays a critical role in maintaining cellular protein homeostasis, regulating processes like cell cycle progression, DNA repair, and stress responses. Dysregulation of PSMD8 has been linked to cancers, neurodegenerative disorders (e.g., Alzheimer’s disease), and autoimmune conditions, highlighting its biological and clinical relevance.

PSMD8 antibodies are widely used in research to study proteasome structure, function, and dynamics. They enable detection of endogenous PSMD8 expression via techniques such as Western blotting, immunoprecipitation, and immunohistochemistry. These tools help elucidate UPS-related mechanisms in disease models, screen for proteasome inhibitors in drug discovery, and explore therapeutic strategies targeting proteasome dysfunction. Commercial PSMD8 antibodies are typically raised against specific epitopes (e.g., human PSMD8 amino acid residues 1-150) and validated for cross-reactivity in common model organisms. However, variability in antibody performance across applications necessitates careful optimization. Recent studies also investigate PSMD8's role in immune regulation, as its overexpression in tumors may correlate with immunotherapy resistance.